Dose-Escalated Radiation Therapy for Pancreatic Cancer: A Simultaneous Integrated Boost Approach.

Humans Organs at Risk Pancreatic Neoplasms / radiotherapy Radiotherapy Dosage Radiotherapy Planning, Computer-Assisted Radiotherapy, Intensity-Modulated

Journal

Practical radiation oncology
ISSN: 1879-8519
Titre abrégé: Pract Radiat Oncol
Pays: United States
ID NLM: 101558279

Informations de publication

Date de publication:
Historique:
received: 18 10 2019
revised: 17 01 2020
accepted: 27 01 2020
pubmed: 18 2 2020
medline: 7 8 2021
entrez: 17 2 2020
Statut: ppublish

Résumé

To provide a detailed description of practical approaches to dose escalation in pancreatic cancer. The current paper represents an international collaborative effort of radiation oncologists from the MR-linac consortium with expertise in pancreatic dose escalation. A 15-fraction hypofractionated intensity modulated radiation therapy (67.5 Gy in 15 fractions) and 5-fraction stereotactic body radiation therapy case (50 Gy in 5 fractions) are presented with information regarding patient selection, target volumes, organs at risk, dose constraints, and specific considerations regarding quality assurance. Additionally, we address barriers to dose escalation and briefly discuss future directions in dose escalation for pancreatic cancer, including particle therapy and magnetic resonance guided radiation therapy. This article on dose escalation for pancreatic cancer may help to guide academic and community based physicians and to serve as a reference for future therapeutic trials.

Identifiants

DOI: 10.1016/j.prro.2020.01.012 PMID: 32061993 PMC: PMC7423616
pubmed: 32061993
pii: S1879-8500(20)30035-7
doi: 10.1016/j.prro.2020.01.012
pmc: PMC7423616
mid: NIHMS1560808
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e495-e507

Subventions

Organisme : NCI NIH HHS
ID : U01 CA200468
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA210181
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA252965
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA218004
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA143837
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA196403
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA221971
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA221707
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA214263
Pays : United States

Informations de copyright

Copyright © 2020 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.

Références

Med Dosim. 2015 Spring;40(1):47-52
pubmed: 25445989
Radiother Oncol. 2019 Mar;132:55-62
pubmed: 30825970
Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2):296-303
pubmed: 27475674
Radiother Oncol. 2017 Jun;123(3):438-445
pubmed: 28464997
J Gastroenterol. 2014 Jun;49(6):1074-80
pubmed: 23846547
Cancer. 2015 Apr 1;121(7):1128-37
pubmed: 25538019
Int J Radiat Oncol Biol Phys. 2017 Dec 1;99(5):1111-1120
pubmed: 28943075
Int J Radiat Oncol Biol Phys. 2010 Dec 1;78(5):1420-6
pubmed: 20399033
Radiother Oncol. 2019 Jul;136:37-43
pubmed: 31015127
Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):181-8
pubmed: 21549517
Lancet. 2014 Jun 21;383(9935):2127-35
pubmed: 24656685
Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1017-21
pubmed: 15001240
J Radiat Res. 2016 Aug;57 Suppl 1:i53-i57
pubmed: 27029741
Am J Clin Oncol. 2019 Mar;42(3):247-252
pubmed: 30724781
Int J Radiat Oncol Biol Phys. 2018 Aug 1;101(5):1212-1221
pubmed: 29907490
Pract Radiat Oncol. 2019 Sep - Oct;9(5):322-332
pubmed: 31474330
Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):101-110
pubmed: 30684663
Radiother Oncol. 2012 Apr;103(1):25-31
pubmed: 22300608
Adv Radiat Oncol. 2017 Mar 18;2(3):403-415
pubmed: 29114609
Cancer Med. 2019 May;8(5):2123-2132
pubmed: 30932367
Adv Radiat Oncol. 2018 Oct 23;3(4):693-700
pubmed: 30370371
Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):858-866
pubmed: 30061007
Cancer. 2009 Feb 1;115(3):665-72
pubmed: 19117351
Int J Radiat Oncol Biol Phys. 2016 Mar 15;94(4):755-65
pubmed: 26972648
JAMA. 2016 May 3;315(17):1844-53
pubmed: 27139057
Br J Radiol. 2017 May;90(1073):20160667
pubmed: 28256898
Arch Pathol Lab Med. 2009 Mar;133(3):413-22
pubmed: 19260747
Lancet Oncol. 2016 Jun;17(6):801-810
pubmed: 27160474
Am J Clin Oncol. 2016 Feb;39(1):1-7
pubmed: 26132367
Clin Oncol (R Coll Radiol). 2018 Nov;30(11):720-727
pubmed: 30197095

Auteurs

Eugene J Koay (EJ)

The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: ekoay@mdanderson.org.

Alexander N Hanania (AN)

Baylor College of Medicine, Houston, Texas.

William A Hall (WA)

Medical College of Wisconsin, Milwaukee, Wisconsin.

Cullen M Taniguchi (CM)

The University of Texas MD Anderson Cancer Center, Houston, Texas.

Neal Rebueno (N)

The University of Texas MD Anderson Cancer Center, Houston, Texas.

Sten Myrehaug (S)

Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada.

Katharine L Aitken (KL)

The Royal Marsden, London, England.

Laura A Dawson (LA)

Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

Christopher H Crane (CH)

Memorial Sloan Kettering Cancer Center, New York City, New York.

Joseph M Herman (JM)

The University of Texas MD Anderson Cancer Center, Houston, Texas.

Beth Erickson (B)

Medical College of Wisconsin, Milwaukee, Wisconsin.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Dose-Escalated Radiation Therapy for...
questionsmedicales.fr › Régions du corps › Organes à risque › Dose-Escalated Radiation Therapy for...
questionsmedicales.fr › Maladies endocriniennes › Tumeurs des glandes endocrines › Tumeurs du pancréas › Dose-Escalated Radiation Therapy for...
questionsmedicales.fr › Thérapeutique › Radiothérapie › Dosimétrie en radiothérapie › Dose-Escalated Radiation Therapy for...
questionsmedicales.fr › Sciences de l'information › Informatique › Informatique médicale › Applications de l'informatique médicale › Prise de décision assistée par ordinateur › Thérapie assistée par ordinateur › Radiothérapie assistée par ordinateur › Planification de radiothérapie assistée par ordinateur › Dose-Escalated Radiation Therapy for...
questionsmedicales.fr › Sciences de l'information › Informatique › Informatique médicale › Applications de l'informatique médicale › Prise de décision assistée par ordinateur › Thérapie assistée par ordinateur › Radiothérapie assistée par ordinateur › Radiothérapie conformationnelle › Radiothérapie conformationnelle avec modulation d'intensité › Dose-Escalated Radiation Therapy for...